More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read more...

Sponsor a Student

SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.

Read more...

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

Read more...

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

Read more...

An Oil Change is Not a Gasket Change: Insights from the Interaction of “Old Blood” and Senolytic Therapy

When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.

Read more...

Kneecapped by Aging: New and Scrutinized Science Suggests Why the UNITY Osteoarthritis Trial Failed

UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.

Read more...

SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?

A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.

Read more...

Announcing the Biomarkers of Aging Consortium

A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can